GANX

Gain Therapeutics is a clinical-stage biotech with effectively no commercial revenue — FY2023 booked just $55.2K and FY2024/FY2025 show none — so the headline P/S of 1515.7x is meaningless. The entire equity value rests on one lead asset, GT-02287, an allosteric small-molecule for Parkinson's disease still in early-stage trials. Per the MD&A, GT-02287 has completed Phase 1a and a bioavailability study and is in a two-part Phase 1b safety/tolerability study (19 of 21 patients completed Part 1, with full Part 1 analysis to be presented 'throughout 2026' and Part 2 due to complete September 2026). This is a binary, pre-efficacy science bet, not a fundamentals story.

The financials read as a textbook cash-burn shell. FY2025 net loss was -$20.2M on operating cash flow of -$18.5M, against $20.8M of cash — roughly one year of runway. Critically, the 10-K itself states there is 'substantial doubt about our ability to continue as a going concern,' flags the need to raise additional capital 'on terms that may not be acceptable to us, or at all,' and warns of Nasdaq continued-listing risk. Shares outstanding already jumped 52.0% YoY to 42.2M, so the FY2025 equity (+152.9%) and cash (+100.6%) improvements were bought with heavy dilution, and more is coming. R&D was actually cut 5.4%, an odd signal for a company supposedly accelerating toward Phase 2.